We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer Transfers Glaucoma Drug to N.Y. Biotech, Ensuring Continued Supply
Pfizer Transfers Glaucoma Drug to N.Y. Biotech, Ensuring Continued Supply
Pfizer has announced that it will transfer the rights for Phospholine Iodide (echothiophate iodide), a treatment for a rare type of glaucoma, to New York-based biotech Fera Pharmaceuticals to ensure a continued supply of the decades-old drug that the company stopped distributing in May.